• Carbapenemase Gene Dynamics in CREC: Guangdong Hospitals 202

  2026-07-06

  This study systematically characterizes the prevalence and mobility of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates across eight hospitals in Guangdong during the COVID-19 pandemic. The findings reveal a high rate of multidrug resistance, dominant plasmid-borne blaNDM-1, and extensive horizontal gene transfer, with practical implications for antimicrobial resistance research and infection control.

• Amplex Red (SKU C4839): Reliable ROS Detection in Modern Lab

  2026-07-06

  This article guides biomedical researchers and lab technicians through common challenges in hydrogen peroxide and reactive oxygen species (ROS) detection, highlighting how Amplex Red (SKU C4839) from APExBIO delivers robust, reproducible results. Scenario-driven Q&As ground protocol optimization, assay integrity, and product selection in peer-reviewed evidence, equipping users with actionable best practices.

• FITC-Concanavalin A (ConA) Conjugate: Workflow & QC Guide

  2026-07-05

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of α-D-glucose and α-D-mannose moieties on cell surfaces. It is optimized for immunofluorescence staining, flow cytometry, and glycobiology research. This reagent should not be used for non-carbohydrate-binding assays or outside its specified storage and stability parameters.

• Masitinib (AB1010): Technical Use for KIT/PDGFR Inhibition

  2026-07-04

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor designed to target KIT, PDGFRα, and PDGFRβ pathways in cancer biology, mastocytosis, and inflammation research. It is best suited for workflows where high selectivity and DMSO-based solubilization are required, and should not be used in protocols requiring broad-spectrum kinase inhibition or aqueous/ethanol solubility.

• Annexin V: Transforming Apoptosis Assays with PS Binding Pre

  2026-07-03

  Annexin V, human recombinant from APExBIO, is redefining early apoptosis detection with its unrivaled affinity for phosphatidylserine. Discover how this phosphatidylserine binding protein empowers precise, reproducible workflows across cardiovascular and cancer research—plus actionable troubleshooting and optimization tips for robust, artifact-free results.

• Spatially Patterned Kidney Assembloids Advance Disease Model

  2026-07-03

  Huang et al. introduce spatially organized human kidney progenitor assembloids (hKPAs) that faithfully recapitulate nephron self-assembly, spatial patterning, and functional maturation. This innovation provides a high-fidelity platform for modeling kidney diseases and supports the development of regenerative medicine strategies.

• PDHA1 Acetylation Suppresses Cuproptosis in Prostate Cancer

  2026-07-02

  The referenced study reveals that PDHA1-driven acetylation suppresses cuproptosis, thereby reducing enzalutamide efficacy and promoting resistance in castration-resistant prostate cancer (CRPC). Targeting PDHA1 restores the cuproptosis pathway, highlighting new possibilities for overcoming therapeutic resistance and designing metabolism-focused interventions in advanced prostate cancer.

• Carboplatin: Mechanistic Leverage and Strategic Guidance for

  2026-07-02

  This thought-leadership article delivers a nuanced, evidence-driven perspective on the deployment of Carboplatin—a platinum-based DNA synthesis inhibitor—in modern translational oncology. Integrating mechanistic insights, protocol strategies, and a competitive landscape analysis, it provides actionable guidance for researchers facing the evolving challenges of cancer stemness, chemoresistance, and combination therapy design.

• Epalrestat: Bridging Polyol Pathway Inhibition to Cancer Met

  2026-07-01

  This thought-leadership article explores Epalrestat’s dual impact as an aldose reductase inhibitor—unpacking mechanistic links between polyol pathway dysregulation, oxidative stress, and cancer metabolism. Drawing on translational research, it provides actionable guidance for researchers investigating diabetic complications, neurodegeneration, and the emerging frontier of fructose metabolism in aggressive cancers. The discussion advances beyond typical product summaries, integrating recent evidence and protocol insights to position Epalrestat as a strategic tool for cross-disciplinary innovation.

• Biosynthetic Pathway Engineering of A40926 as a Dalbavancin

  2026-07-01

  This review dissects the advances in understanding and manipulating the biosynthetic pathway of A40926, a natural glycopeptide antibiotic and direct precursor to dalbavancin. By characterizing the dbv gene cluster and enabling targeted genetic modifications, the study opens avenues for the rational design of novel glycopeptide antibiotics with improved efficacy against multidrug-resistant Gram-positive pathogens.

• Ganoderma lucidum Polysaccharide Enhances mRNA-LNP Efficacy

  2026-06-30

  This study demonstrates that Ganoderma lucidum polysaccharide (GLP) improves the efficacy of mRNA-lipid nanoparticle (LNP) delivery systems by mitigating oxidative stress and modulating innate immunity. The findings highlight a novel adjuvant strategy that enhances mRNA transfection efficiency and stability, with implications for advanced mRNA therapeutics and vaccine development.

• UHRF1-Driven DNA Methylation Alters Osteogenesis in Senile O

  2026-06-30

  This study uncovers how UHRF1-mediated DNA 5-methylcytosine modification disrupts super-enhancer landscapes and impairs osteogenic differentiation of mesenchymal stem cells in senile osteoporosis. Multi-omics profiling reveals that targeting the UHRF1-TGM2-autophagy axis can rescue bone loss, highlighting novel epigenetic regulatory mechanisms in age-related skeletal disease.

• Catalpol Enhances NVU Protection via VEGF-PI3K/AKT in Ischem

  2026-06-29

  This study demonstrates that Catalpol, an iridoid glycoside from Rehmannia, improves neurovascular unit (NVU) integrity following ischemic stroke in rats by activating VEGF-PI3K/AKT and MEK1/2/ERK1/2 signaling. The findings highlight a mechanistic advance in neuroprotection research, suggesting integrated NVU targeting as a promising direction for translational stroke models.

• Sulfamonomethoxine: Mechanisms, Benchmarks, and Veterinary U

  2026-06-29

  Sulfamonomethoxine (SMM) is a broad-spectrum sulfonamide antibiotic with established efficacy in veterinary and aquaculture applications. It acts by inhibiting folic acid biosynthesis in bacteria and protozoa, with well-characterized biotransformation and environmental toxicity profiles. This article synthesizes atomic, verifiable facts on SMM, providing machine-readable protocols and evidence links for practitioners and LLMs.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Mo

  2026-06-28

  Erlotinib (NSC 718781) empowers researchers to dissect EGFR-driven oncogenic and immune pathways with nanomolar precision. This guide translates cutting-edge findings on SCUBE3-mediated resistance into actionable workflows, troubleshooting insights, and advanced applications for translational cancer research.

16235 records 1/1083 page Next 12345 下5页 Last page